Blueprint Medicines (BPMC) Tops Q3 EPS by $3.50

Blueprint Medicines (NASDAQ: BPMC) reported Q3 EPS of $11.16, $3.50 better than the analyst estimate of $7.66. Revenue for the quarter came in at $745.1 million versus the consensus estimate of $628.68 million.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.

You May Also Be Interested In

• Nomura/Instinet Upgrades Genting Singapore (GENS:SP) (GIGNY) to Neutral
• Tenon Medical (TNON) Misses Q2 EPS by 395c
• Workhorse Group (WKHS) Misses Q2 EPS by 77c